Pharmacologic approaches to reversing multidrug resistance.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Seminars in hematology (Print)

• Publication date

  1997-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 9408960
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins*

  1997cited by this paper
• Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.

  1996cited by this paper
• Pharmacological considerations in the modulation of multidrug resistance.

  1996cited by this paper
• In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.

  1996cited by this paper
• Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

  1996cited by this paper
• Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

  1996cited by this paper
• Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.

  1996cited by this paper
• DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.

  1995cited by this paper
• Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

  1995cited by this paper
• Clinical studies with modulators of multidrug resistance.

  1995cited by this paper
• P-glycoprotein in adult solid tumors. Expression and prognostic significance.

  1995cited by this paper
• MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

  1995cited by this paper
• A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study

  1995cited by this paper
• Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways.

  1994cited by this paper
• Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

  1994cited by this paper
• Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection.

  1994cited by this paper
• Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.

  1994cited by this paper
• Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

  1994cited by this paper
• Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites.

  1993cited by this paper
• Modulation of multidrug resistance: at the threshold.

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies.

  1993cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Function and regulation of the human multidrug resistance gene.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells.

  1993cited by this paper
• Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

  1992cited by this paper
• Cyclosporins as drug resistance modifiers.

  1992cited by this paper
• Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

  1992cited by this paper
• Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line.

  1992cited by this paper
• Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity.

  1991cited by this paper
• Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.

  1991cited by this paper
• Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

  1991cited by this paper
• Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

  1990cited by this paper
• Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.

  1989cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

  1988cited by this paper
• Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines.

  1987cited by this paper
• Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.

  1987cited by this paper
• Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

  1987cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper
• Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

  1983cited by this paper
• Mutations of Bacteria from Virus Sensitivity to Virus Resistance.

  1943cited by this paper

• Indolo-quinazoline in Medicinal Chemistry as an Anticancer Agents: Current Trends and Future Opportunities

  2025cites this paper
• Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action

  2020cites this paper
• The challenge of drug resistance in cancer treatment: a current overview

  2018cites this paper
• Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.

  2017cites this paper
• The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts.

  2017cites this paper
• Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).

  2016cites this paper
• Targeting autophagy augments the activity of DHA-E3 to overcome p-gp mediated multi-drug resistance.

  2016cites this paper
• Novel Insights into Combating Cancer Chemotherapy Resistance Using a Plasmonic Nanocarrier: Enhancing Drug Sensitiveness and Accumulation Simultaneously with Localized Mild Photothermal Stimulus of Femtosecond Pulsed Laser

  2014cites this paper
• UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter.

  2014cites this paper
• Modulation of the biologic behaviour of breast cancer; in vitro models and clinical correlates

  2014cites this paper
• Reversal of multidrug resistance by 5,5’-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX

  2013cites this paper
• Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer: A Pilot Study

  2013cites this paper
• status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to

  2013cites this paper
• SYMPOSIUM: HIGHLIGHTS FROM THE FIRST COMBINED 2011 MEETING OF THE MUSCULO- SKELETAL TUMOR SOCIETY AND CONNECTIVE TISSUE ONCOLOGY SOCIETY Lipid-functionalized Dextran Nanosystems to Overcome Multidrug Resistance in Cancer

  2013cites this paper
• Microparticles and their emerging role in cancer multidrug resistance.

  2012cites this paper
• BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.

  2012cites this paper
• Sesquiterpenos dihidro-β-agarofuranos como revertidores naturales de la resistencia celular a múltiples fármacos causada por la Glicoproteína-P MDR1 humana

  2011cites this paper
• Improving delivery of molecularly targeted agents to glioma

  2011cites this paper
• Principles of Chemotherapy

  2011cites this paper
• Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

  2011cites this paper
• A novel podophyllotoxin derivative (YB-1EPN) induces apoptosis and down-regulates express of P-glycoprotein in multidrug resistance cell line KBV200.

  2010cites this paper
• Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma

  2010cites this paper
• Pharmacological modulation and manipulation of cancer drug resistance

  2010cites this paper
• Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group

  2010cites this paper
• Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

  2009cites this paper
• NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance

  2009cites this paper
• Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival

  2009cites this paper
• Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma

  2009cites this paper
• Challenging patient populations in breast cancer: Taxane resistance and triple‐negative receptor subtype

  2008cites this paper
• Taxanes, microtubules and chemoresistant breast cancer.

  2008cites this paper
• Tumor targeting using liposomal antineoplastic drugs

  2008cites this paper
• Mogoltacin enhances vincristine cytotoxicity in human transitional cell carcinoma (TCC) cell line.

  2008cites this paper
• Chapter 49 – Natural and Acquired Resistance to Cancer Therapies

  2008cites this paper
• IntestinalTransporters in Drug Absorption

  2008cites this paper
• Characterization of Human Liver Cytochrome P-450 Enzymes Involved in the O-demethylation of a New P-glycoprotein Inhibitor HM-30181

  2007cites this paper
• Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.

  2007cites this paper
• Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

  2007cites this paper
• Di(2-ethylhexyl)phthalate leached from medical PVC devices serves as a substrate and inhibitor for the P-glycoprotein.

  2007cites this paper
• Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice

  2007cites this paper
• Les poisons du fuseau

  2007cites this paper
• Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy.

  2006cites this paper
• Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry.

  2006cites this paper
• Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/electrospray mass spectrometry.

  2006cites this paper
• High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

  2006cites this paper
• Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

  2005cites this paper
• A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

  2005cites this paper
• Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.

  2005cites this paper
• The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

  2005cites this paper
• Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.

  2005cites this paper
• In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.

  2005cites this paper
• Celastraceae Sesquiterpenes as a New Class of Modulators That Bind Specifically to Human P-Glycoprotein and Reverse Cellular Multidrug Resistance

  2004cites this paper
• n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia

  2004cites this paper
• Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

  2004cites this paper
• Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.

  2004cites this paper
• Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide

  2004cites this paper
• Screening novel, potent multidrug-resistant modulators from imidazole derivatives.

  2004cites this paper
• Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance

  2004cites this paper
• Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR.

  2004cites this paper
• Effect of Verapamil on Cellular Uptake of Tc-99m MIBI and Tetrofosmin on Several Cancer Cells

  2004cites this paper
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  2004cites this paper
• Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.

  2003cites this paper
• CHAPTER 5 – SUBSTRATE-BINDING SITES IN ABC TRANSPORTERS

  2003cites this paper
• Persistent reversal of P‐glycoprotein‐mediated daunorubicin resistance by tetrandrine in multidrug‐resistant human T lymphoblastoid leukemia MOLT‐4 cells

  2003cites this paper
• FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.

  2003influential citation
• FTY720 stimulates multidrug transporter– and cysteinyl leukotriene–dependent T cell chemotaxis to lymph nodes

  2003cites this paper
• Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines

  2003cites this paper
• Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle.

  2003cites this paper
• Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia

  2003cites this paper
• Therapeutic ultrasound: Its application in drug delivery

  2002cites this paper
• Homocamptothecin-Daunorubicin Association Overcomes Multidrug-Resistance in Breast Cancer MCF7 Cells

  2002cites this paper
• Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.

  2002cites this paper
• Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters

  2002cites this paper
• Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

  2002cites this paper
• Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients

  2002influential citation
• Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin).

  2002cites this paper
• Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents.

  2002cites this paper
• The medicinal chemistry of multidrug resistance (MDR) reversing drugs.

  2002cites this paper
• Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.

  2001cites this paper
• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  2001cites this paper
• Ultrasound-Induced Hyperthermia Increases Cellular Uptake and Cytotoxicity of P-Glycoprotein Substrates in Multi-Drug Resistant Cells

  2001cites this paper
• In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator , XR 9576

  2001cites this paper
• Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

  2001cites this paper
• Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.

  2001cites this paper
• Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators.

  2001cites this paper
• Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes.

  2001cites this paper
• MDR-1 Expression and Deletions of Chromosomes 7 and 5(Q) Separately Indicate Adverse Prognosis in AML

  2001cites this paper
• The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers.

  2001cites this paper
• Modulation of cancer cell multidrug resistance by an extract of Ficus citrifolia.

  2001cites this paper
• Preferential cytotoxicity for multidrug-resistant K562 cells using the combination of a photosensitizer and a cyanine dye.

  2000cites this paper
• Effects of Multidrug Resistance Gene Expression in Acute Erythroleukemia

  2000influential citation
• The Effect of Fatty Acids and Analogues upon Intracellular Levels of Doxorubicin in Cells Displaying P-Glycoprotein Mediated Multidrug Resistance

  2000cites this paper
• Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.

  2000cites this paper
• Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines.

  2000cites this paper
• Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates

  2000cites this paper
• Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research.

  2000cites this paper
• Adenosine triphosphate-binding cassette proteins and bioavailability: "we can pump you up (or out)".

  2000cites this paper
• Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.

  2000cites this paper
• Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells

  2000cites this paper
• Regulation of MDR1 gene expression: emerging concepts.

  2000cites this paper
• Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

  2000cites this paper